Dianthus Therapeutics (DNTH) Stock Price, News & Analysis

Company Overview

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Key Stats

• Today's Range: $34.60 to $36.79
• 50-Day Range: $18.76 to $39.55
• 52-Week Range: $13.36 to $40.16
• Volume: 525,015 shs
• Average Volume: 687,403 shs
• Market Capitalization: $1.17 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.88
• Consensus Rating: Moderate Buy

Dianthus Therapeutics Stock Analysis - MarketRank™

Dianthus Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 381st out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Dianthus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 10 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Dianthus Therapeutics has a consensus price target of $60.88, representing about 68.2% upside from its current price of $36.20.

Amount of Analyst Coverage

Dianthus Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($2.61) to ($3.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dianthus Therapeutics is -11.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dianthus Therapeutics is -11.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dianthus Therapeutics has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

17.63% of the float of Dianthus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dianthus Therapeutics has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Dianthus Therapeutics has recently decreased by 8.24%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dianthus Therapeutics does not currently pay a dividend.

Dividend Growth

Dianthus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.63% of the float of Dianthus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dianthus Therapeutics has a short interest ratio ("days to cover") of 8.7.

Change versus previous month

Short interest in Dianthus Therapeutics has recently decreased by 8.24%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.68

News Sentiment

Dianthus Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Dianthus Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 9 people have searched for DNTH on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.

MarketBeat Follows

1 people have added Dianthus Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Dianthus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $700,000.00 in company stock.

Percentage Held by Insiders

Only 8.15% of the stock of Dianthus Therapeutics is held by insiders.

Percentage Held by Institutions

47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DNTH Stock Analysis - Frequently Asked Questions

How have DNTH shares performed this year?

Dianthus Therapeutics' stock was trading at $21.80 at the beginning of the year. Since then, DNTH shares have increased by 66.1% and is now trading at $36.20.

How were Dianthus Therapeutics' earnings last quarter?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) released its earnings results on Thursday, August, 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by $0.02. The business earned $0.19 million during the quarter, compared to the consensus estimate of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative trailing twelve-month return on equity of 34.72%.

How do I buy shares of Dianthus Therapeutics?

Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dianthus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dianthus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/15/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DNTH
• CIK: 1690585
• Web: dianthustx.com
• Phone: 857-242-0170
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Dianthus Therapeutics: $60.88
• High Price Target: $100.00
• Low Price Target: $40.00
• Potential Upside/Downside: +68.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$84.97 million
• Net Margins: -2,364.56%
• Pretax Margin: -2,364.60%
• Return on Equity: -34.72%
• Return on Assets: -32.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.12
• Quick Ratio: 13.12

Sales & Book Value

• Annual Sales: $6.24 million
• Price / Sales: 186.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.91 per share
• Price / Book: 3.04

Miscellaneous

• Outstanding Shares: 32,190,000
• Free Float: 29,565,000
• Market Cap: $1.17 billion
• Optionable: Optionable
• Beta: 1.58